Originally Aired: November 21, 2022
Time: 8:00 am PT, 11:00 am ET, 17:00 CET
Drugging traditionally undruggable targets is witnessing a sea change due to the development of novel therapeutic modalities. A revolution that began with the therapeutic use of monoclonal antibodies in the 1970s, has expanded into novel therapeutic modalities that involve antisense oligonucleotides, recombinant proteins, viral gene therapies, cellular immunotherapies, ex vivo gene therapies such as CAR-T cells, mRNA and RNAi therapies, microbiome, PROTACs and more. Such novel modalities are creating new hope for patients suffering from diseases like cancer, Alzheimer’s disease and multiple sclerosis, and various diseases that were previously untreatable. Research shows novel therapeutics modalities can accomplish complex functions in ways that traditional drugs cannot. The design of Certified Good Manufacturing Practices (cGMP) manufacturing facilities to produce novel therapeutics requires detailed planning and consideration of several factors, including throughput, biosafety levels, product segregation and contamination control, regulatory environment, time to market and tech transfer challenges.
In this session of Learning Labs, we talk to Katarina Stenklo, Enterprise Solutions Commercial Activation Leader at Cytiva, about the production of therapeutics based on viral vectors, plasmid DNA and mRNA. Katarina is part of a dynamic team at Cytiva that provides integrated manufacturing solutions for advanced therapies with a focus on accelerated timelines and quality.
A live Q&A session followed the presentation, offering a chance to pose questions to our expert panelist.
Produced with support from: